The systemic and kidney hemodynamic response to empagliflozin, losartan and their combination varies between individuals
Our data show large individual variability in response to treatment with the ARB losartan and the SGLT2i empagliflozin. Clinicians should monitor treatment responses in patients and consider switching from one kidney protective drug to another in non-responders.
Authors
- Rosalie A. Scholtes (ORCID: https://orcid.org/0000-0002-2794-2263)
- Charlotte M. Mosterd (ORCID: https://orcid.org/0000-0002-1309-5155)
- Anne C. Hesp (ORCID: https://orcid.org/0000-0001-5934-2425)
- Daniël H. van Raalte (ORCID: https://orcid.org/0000-0003-2894-6124)
- Britt Eveline Wever
- Mark M. Smits (ORCID: https://orcid.org/0000-0001-8236-8842)
- Hiddo Jan L. Heerspink
Institutions
- University Medical Center Groningen (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1007/s40620-025-02289-3
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Boehringer Ingelheim